# Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement

> **NCT04062695** · PHASE2 · UNKNOWN · sponsor: **Charite University, Berlin, Germany** · enrollment: 80 (estimated)

## Conditions studied

- Psoriatic Arthritis
- Spondylitis
- Sacroilitis

## Interventions

- **DRUG:** Tofacitinib 5 MG Oral Tablet [Xeljanz]
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04062695
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-04
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04062695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04062695, "Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04062695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*